Summary by Moomoo AI
Bristol-Myers Squibb (BMS) announced the virtual 2024 Annual Meeting of Shareholders to be held on May 7, 2024. Shareholders of record as of March 14, 2024, are entitled to vote on several key proposals, including the election of 10 board directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as the independent auditor, and an amendment to the Certificate of Incorporation for limited officer exculpation. Additionally, three shareholder proposals will be considered. The Board recommends votes for the election of directors, executive compensation, auditor ratification, and the charter amendment, but against all shareholder proposals. The meeting will also address the CEO transition, with Dr. Christopher Boerner succeeding Dr. Giovanni Caforio. BMS emphasizes the meeting's accessibility and the ability for shareholders to participate virtually.